NHL
MCID: LYM143
MIFTS: 74

Lymphoma, Non-Hodgkin, Familial (NHL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymphoma, Non-Hodgkin, Familial

MalaCards integrated aliases for Lymphoma, Non-Hodgkin, Familial:

Name: Lymphoma, Non-Hodgkin, Familial 57 38 40
Non-Hodgkin Lymphoma 57 12 75 59 29 6 15
Lymphoma, Non-Hodgkin 57 13 44 72
Nhl 57 59 74
Lymphoma, Non-Hodgkin, Somatic 57
Lymphoma, Follicular, Somatic 57
Familial Non-Hodgkin Lymphoma 74
Non-Hodgkin Lymphoma; Nhl 57
Lymphoma Non-Hodgkins 55
Non-Hodgkin Lymphomas 15
Non-Hodgkins Lymphoma 17

Characteristics:

Orphanet epidemiological data:

59
non-hodgkin lymphoma
Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060060
OMIM 57 605027
MeSH 44 D008228
ICD10 33 C85.7 C85.9
MESH via Orphanet 45 D008228
UMLS via Orphanet 73 C0024305
Orphanet 59 ORPHA547
UMLS 72 C0024305

Summaries for Lymphoma, Non-Hodgkin, Familial

UniProtKB/Swiss-Prot : 74 Familial non-Hodgkin lymphoma: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.

MalaCards based summary : Lymphoma, Non-Hodgkin, Familial, also known as non-hodgkin lymphoma, is related to anaplastic large cell lymphoma and lymphoma, mucosa-associated lymphoid type. An important gene associated with Lymphoma, Non-Hodgkin, Familial is CASP10 (Caspase 10), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Entecavir and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are lymphoma and Reduced mammosphere formation

Disease Ontology : 12 A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.

Wikipedia : 75 Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphoma except... more...

More information from OMIM: 605027

Related Diseases for Lymphoma, Non-Hodgkin, Familial

Diseases related to Lymphoma, Non-Hodgkin, Familial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 948)
# Related Disease Score Top Affiliating Genes
1 anaplastic large cell lymphoma 35.0 PTPRC PAX5 NPM1 ALK
2 lymphoma, mucosa-associated lymphoid type 34.8 IRF4 CD5 CCND1 BCL6 BCL10
3 composite lymphoma 34.5 PAX5 CD5 BCL6
4 reticulosarcoma 34.5 PTPRC PAX5 NPM1 BCL6 ALK
5 plasmablastic lymphoma 34.5 PTPRC MYC MS4A1 BCL6
6 richter's syndrome 34.5 TP53 MYC IRF4 CD5
7 mantle cell lymphoma 34.3 TP53 PTPRC PAX5 MYC CD5 CCND1
8 follicular lymphoma 1 34.2 BCL6 BCL10
9 primary mediastinal large b-cell lymphoma 33.4 MYC IRF4 BCL6
10 lymphoma, hodgkin, classic 33.3 PTPRC PAX5 CD5 BCL6 ALK
11 burkitt lymphoma 33.2 PAX5 MYC MS4A1 BCL6
12 lymphoma 33.0 PAX5 NPM1 MYC CCND1 CASP10 BCL6
13 cll/sll 33.0 TP53 PAX5 CD5 CCND1
14 myeloma, multiple 33.0 TP53 PTPRC NRAS MYC IRF4 CCND1
15 lymphoblastic lymphoma 33.0 PTPRC CD5 BCL6
16 lymphosarcoma 32.8 PTPRC CD5 BCL6
17 leukemia, acute myeloid 32.7 TP53 PTPRC NRAS NPM1 MYC
18 acquired immunodeficiency syndrome 32.6 TP53 MYC BCL6
19 gastric lymphoma 32.5 TP53 BCL6 BCL10
20 lymphoproliferative syndrome 32.5 PRF1 NRAS CASP10
21 primary effusion lymphoma 32.5 MYC IRF4 BCL6
22 diffuse large b-cell lymphoma 32.5 TP53 MYC IRF4 CD5 BCL6 BCL10
23 follicular lymphoma 32.5 MYC IRF4 CCND1 BCL6 BCL10
24 lymphocytic leukemia 32.4 TP53 PAX5 MYC CD5
25 hodgkin's lymphoma, lymphocytic-histiocytic predominance 32.4 PTPRC BCL6
26 marginal zone b-cell lymphoma 32.3 IRF4 CD5 CCND1 BCL6 BCL10
27 adenocarcinoma 32.3 TP53 PIK3CA MYC CCND1 BRAF ALK
28 splenic marginal zone lymphoma 32.3 PAX5 CD5 BCL6
29 breast lymphoma 32.2 CD5 BCL6
30 skin melanoma 32.2 TP53 NRAS BRAF
31 glioblastoma 32.2 TP53 PIK3CA NRAS MYC CCND1 BRAF
32 hematologic cancer 32.2 TP53 PTPRC PAX5 NPM1 MYC CD5
33 plasmacytoma 32.2 PTPRC MYC IRF4
34 leukemia, chronic lymphocytic 32.1 TP53 PAX5 NRAS MS4A1 CD5 CCND1
35 adult lymphoma 32.1 MYC CD5 ALK
36 prolymphocytic leukemia 32.1 MYC CD5 CCND1
37 lung lymphoma 32.1 PAX5 CD5 BCL6 ALK
38 peripheral t-cell lymphoma 32.1 MS4A1 CD5 BCL6 ALK
39 nasopharyngeal carcinoma 32.0 TP53 PIK3CA NRAS MYC CCND1
40 glioblastoma multiforme 32.0 TP53 PIK3CA MYC CCND1
41 cholangiocarcinoma 31.9 TP53 PIK3CA CCND1 BRAF
42 autoimmune lymphoproliferative syndrome 31.9 PTPRC PRF1 NRAS CASP10
43 hairy cell leukemia 31.9 CD5 CCND1 BRAF
44 nodular lymphocyte predominant hodgkin lymphoma 31.8 PAX5 BCL6
45 histiocytoma 31.8 TP53 PTPRC ALK
46 plasma cell leukemia 31.8 IRF4 CCND1
47 brain cancer 31.7 TP53 PIK3CA NRAS MYC BRAF ALK
48 intestinal disease 31.7 TP53 PIK3CA MYC CCND1 BCL6
49 lung cancer susceptibility 3 31.7 TP53 PIK3CA NRAS CCND1 BRAF ALK
50 b cell prolymphocytic leukemia 31.7 TP53 MYC MS4A1 CD5

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin, Familial:



Diseases related to Lymphoma, Non-Hodgkin, Familial

Symptoms & Phenotypes for Lymphoma, Non-Hodgkin, Familial

Human phenotypes related to Lymphoma, Non-Hodgkin, Familial:

32
# Description HPO Frequency HPO Source Accession
1 lymphoma 32 HP:0002665

Clinical features from OMIM:

605027

GenomeRNAi Phenotypes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.5 BCL6 BRAF CCND1 CD5 MYC NRAS
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 BCL10 RAD54B RAD54L TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 BCL10 BRAF CCND1 MYC RAD54B RAD54L

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin, Familial:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 BCL10 BCL6 BRAF CCND1 IRF4 MYC
2 hematopoietic system MP:0005397 10.41 BCL10 BCL6 BRAF CCND1 CD5 IRF4
3 immune system MP:0005387 10.38 BCL10 BCL6 BRAF CCND1 CD5 IRF4
4 growth/size/body region MP:0005378 10.34 ALK BCL6 BRAF CCND1 IRF4 MYC
5 homeostasis/metabolism MP:0005376 10.31 ALK BCL6 BRAF CCND1 IRF4 MYC
6 endocrine/exocrine gland MP:0005379 10.28 ALK BCL10 BCL6 BRAF CCND1 MYC
7 mortality/aging MP:0010768 10.28 ALK BCL10 BCL6 BRAF CCND1 MYC
8 integument MP:0010771 10.16 ALK BRAF CCND1 CD5 MYC NPM1
9 neoplasm MP:0002006 10.15 ALK BRAF CCND1 IRF4 MYC NPM1
10 nervous system MP:0003631 10.1 ALK BCL10 BRAF CCND1 CD5 MYC
11 liver/biliary system MP:0005370 10.03 BCL6 BRAF MYC NPM1 NRAS PRF1
12 normal MP:0002873 9.85 BCL6 BRAF CCND1 CD5 MYC NRAS
13 no phenotypic analysis MP:0003012 9.8 BCL6 CD5 MYC NRAS PIK3CA PTPRC
14 pigmentation MP:0001186 9.35 ALK BRAF MYC NRAS TP53
15 skeleton MP:0005390 9.28 ALK BRAF CCND1 MYC NRAS PAX5

Drugs & Therapeutics for Lymphoma, Non-Hodgkin, Familial

Drugs for Lymphoma, Non-Hodgkin, Familial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 643)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
4
Nitric Oxide Approved Phase 4 10102-43-9 145068
5
Prilocaine Approved Phase 4 721-50-6 4906
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Epirubicin Approved Phase 4 56420-45-2 41867
8
Morphine Approved, Investigational Phase 4 57-27-2 5288826
9
Dacarbazine Approved, Investigational Phase 4 4342-03-4 5351166
10
Ribavirin Approved Phase 4 36791-04-5 37542
11
Fotemustine Investigational Phase 4 92118-27-9
12
Pirarubicin Investigational Phase 4 72496-41-4
13 Anti-Arrhythmia Agents Phase 4
14 Anesthetics, Inhalation Phase 4
15 Sodium Channel Blockers Phase 4
16 Lidocaine, Prilocaine Drug Combination Phase 4
17 Diuretics, Potassium Sparing Phase 4
18 Giapreza Phase 4
19 Angiotensin II Type 1 Receptor Blockers Phase 4
20 Angiotensin Receptor Antagonists Phase 4
21 Hematinics Phase 4
22 Epoetin alfa Phase 4 113427-24-0
23
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
24
Gemcitabine Approved Phase 3 95058-81-4 60750
25
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
26
Rasburicase Approved, Investigational Phase 3 134774-45-1
27
Ondansetron Approved Phase 3 99614-02-5 4595
28
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
29
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 23925 27284
30
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
31
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
32
deoxycholic acid Approved Phase 3 83-44-3 222528
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
34
Dalteparin Approved Phase 3 9005-49-6
35
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
36
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
37
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
38
Tazobactam Approved Phase 3 89786-04-9 123630
39
Piperacillin Approved Phase 3 66258-76-2 43672
40
Vancomycin Approved Phase 3 1404-90-6 441141 14969
41
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
42
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
43
Zoledronic Acid Approved Phase 3 118072-93-8 68740
44
Calcium carbonate Approved, Investigational Phase 3 471-34-1
45
Palivizumab Approved, Investigational Phase 3 188039-54-5
46
Captopril Approved Phase 3 62571-86-2 44093
47
Acyclovir Approved Phase 3 59277-89-3 2022
48
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
49
Blinatumomab Approved, Investigational Phase 3 853426-35-4
50
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253

Interventional clinical trials:

(show top 50) (show all 2308)
# Name Status NCT ID Phase Drugs
1 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
2 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
3 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
4 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
5 Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
6 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
7 Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
8 Evaluation of the Analgesy Using a Local Anesthetic (Lidocaine and Prolocaine) Eutectic Mixture and/or Nitric Oxide at 50% in Oxygen (Livopan®) in Pediatric Patients That During Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;Livopan;EMLA
9 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
10 A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
11 A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens Completed NCT00090038 Phase 4 rituximab
12 A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
13 Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
14 A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
15 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
16 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
17 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
18 The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP Completed NCT00162955 Phase 4 Valsartan
19 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
20 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
21 A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Recruiting NCT01909934 Phase 4 brentuximab vedotin
22 Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL) Recruiting NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
23 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
24 The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma. Recruiting NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
25 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Recruiting NCT03558412 Phase 4 Decitabine
26 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
27 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
28 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
29 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
30 Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study Terminated NCT02717949 Phase 4 sofosbuvir/ledipasvir;sofosbuvir;Ribavirin
31 A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
32 A Pilot/Feasibility Study of Ledipasvir/Sofosbuvir as Treatment for Hepatitis C in Hematopoietic Cell Transplantation (HCT) Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
33 Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission Unknown status NCT00091676 Phase 3
34 A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma Unknown status NCT01570049 Phase 3 Bendamustine
35 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
36 A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL Unknown status NCT00129090 Phase 3 R-CHOEP 14 with 12x Rituximab
37 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
38 Phase III Stidy of Zevalin And BEAM Compared With BEAM Alone Prior to Autologous Hematopoietic Steem Cell Transpl. in Pts Relapse of Non-Hodgkins Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
39 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
40 International Protocol for the Treatment of Childhood Anaplastic Large Cell Lymphoma Unknown status NCT00006455 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;therapeutic hydrocortisone;vinblastine sulfate
41 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
42 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
43 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
44 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
45 A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma Unknown status NCT00078598 Phase 3 Rituximab or Iodine I 131 Tositumomab Therapy
46 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
47 A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
48 A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
49 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
50 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone

Search NIH Clinical Center for Lymphoma, Non-Hodgkin, Familial

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Aldesleukin
bendamustine
Bleomycin
Carmustine
Chlorambucil
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cladribine
Cladribine
Cyclophosphamide
Cytarabine
Etoposide
fludarabine
Fludarabine phosphate
Ifosfamide
Ifosfamide
Lomustine
mercaptopurine
Mitoxantrone
pegaspargase
Procarbazine
Procarbazine
Procarbazine Hydrochloride
Rituximab
sargramostim
Vincristine
Vincristine
Vincristine Sulfate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Non-Hodgkin, Familial cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, non-hodgkin

Genetic Tests for Lymphoma, Non-Hodgkin, Familial

Genetic tests related to Lymphoma, Non-Hodgkin, Familial:

# Genetic test Affiliating Genes
1 Non-Hodgkin Lymphoma 29 BCL10 CASP10 PRF1 RAD54B RAD54L

Anatomical Context for Lymphoma, Non-Hodgkin, Familial

MalaCards organs/tissues related to Lymphoma, Non-Hodgkin, Familial:

41
B Cells, T Cells, Bone, Bone Marrow, Breast, Lymph Node, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Non-Hodgkin, Familial:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Lymphoma, Non-Hodgkin, Familial

Articles related to Lymphoma, Non-Hodgkin, Familial:

(show top 50) (show all 11200)
# Title Authors PMID Year
1
A proportion of patients with lymphoma may harbor mutations of the perforin gene. 38 8 71
15728124 2005
2
Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. 9 38 71
12010812 2002
3
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. 38 8
21796119 2011
4
Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. 38 8
15811955 2005
5
A tumour suppressor network relying on the polyamine-hypusine axis. 8
22722845 2012
6
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. 8
21390126 2011
7
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. 8
20081860 2010
8
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. 8
20054396 2010
9
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. 8
19412164 2009
10
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. 8
18323416 2008
11
Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. 71
16278825 2006
12
BRAF mutations in non-Hodgkin's lymphoma. 71
14612909 2003
13
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 71
12960123 2003
14
Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. 71
12229880 2002
15
Inactivating mutations of the caspase-10 gene in gastric cancer. 71
11973654 2002
16
Age of onset evidence for anticipation in familial non-Hodgkin's lymphoma. 8
10651726 2000
17
Perforin gene defects in familial hemophagocytic lymphohistiocytosis. 71
10583959 1999
18
Mutations in the RAD54 recombination gene in primary cancers. 71
10362365 1999
19
Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. 71
10362364 1999
20
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. 71
1565144 1992
21
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. 9 38
19965662 2010
22
Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop. 9 38
20038219 2010
23
An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males. 9 38
19897031 2010
24
Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. 9 38
20414345 2010
25
A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. 9 38
19748593 2010
26
Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. 9 38
19809881 2010
27
Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphoma. 9 38
19821039 2010
28
Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma. 9 38
19751723 2009
29
Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. 9 38
19917125 2009
30
Speckled-like pattern in the germinal center (SLIP-GC), a nuclear GTPase expressed in activation-induced deaminase-expressing lymphomas and germinal center B cells. 9 38
19734146 2009
31
Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma. 9 38
19396635 2009
32
Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation. 9 38
19137297 2009
33
[Genetic susceptibility of single nucleotide polymorphism in MGMT to non-Hodgkin lymphoma]. 9 38
19954624 2009
34
Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement. 9 38
19811326 2009
35
Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. 9 38
19834627 2009
36
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. 9 38
19388933 2009
37
Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma. 9 38
19452252 2009
38
BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. 9 38
19258594 2009
39
Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. 9 38
19383901 2009
40
Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. 9 38
19225536 2009
41
Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker. 9 38
19100628 2009
42
FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. 9 38
19245433 2009
43
Targeting CD40 in Waldenström's macroglobulinemia. 9 38
19362983 2009
44
Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. 9 38
18981293 2009
45
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. 9 38
19135941 2009
46
Expression of activation-induced cytidine deaminase in malignant lymphomas infiltrating the bone marrow. 9 38
18776814 2008
47
A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. 9 38
18940680 2008
48
Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. 9 38
18546271 2008
49
Primary tracheal lymphoma causing respiratory failure. 9 38
18670314 2008
50
Serum CA125 and PSA concentrations in patients with lymphoma. 9 38
18654120 2008

Variations for Lymphoma, Non-Hodgkin, Familial

ClinVar genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

6 (show top 50) (show all 54)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 RAD54B NM_012415.3(RAD54B): c.1778A> G (p.Asn593Ser) single nucleotide variant Pathogenic rs114216685 8:95403868-95403868 8:94391640-94391640
2 RAD54L NM_003579.4(RAD54L): c.1331T> A (p.Val444Glu) single nucleotide variant Pathogenic rs121908689 1:46738430-46738430 1:46272758-46272758
3 CASP10 NM_032977.3(CASP10): c.1241C> T (p.Ala414Val) single nucleotide variant Pathogenic rs28936699 2:202074111-202074111 2:201209388-201209388
4 CASP10 NM_032977.3(CASP10): c.769C> T (p.Gln257Ter) single nucleotide variant Pathogenic rs121909775 2:202070652-202070652 2:201205929-201205929
5 CASP10 NM_032977.3(CASP10): c.1042_1043insA (p.Gly348fs) insertion Pathogenic rs398122800 2:202073912-202073913 2:201209189-201209190
6 NRAS NM_002524.5(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 1:115258744-115258744 1:114716123-114716123
7 BRAF NM_004333.6(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 7:140481403-140481403 7:140781603-140781603
8 BRAF NM_004333.6(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
9 BRAF NM_004333.6(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 7:140453154-140453154 7:140753354-140753354
10 PRF1 NM_001083116.3(PRF1): c.1122G> A (p.Trp374Ter) single nucleotide variant Pathogenic rs104894176 10:72358355-72358355 10:70598599-70598599
11 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
12 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
13 NRAS NM_002524.5(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 1:115258745-115258745 1:114716124-114716124
14 TP53 NM_000546.5(TP53): c.845G> C (p.Arg282Pro) single nucleotide variant Pathogenic/Likely pathogenic rs730882008 17:7577093-7577093 17:7673775-7673775
15 PIK3CA NM_006218.4(PIK3CA): c.1030G> A (p.Val344Met) single nucleotide variant Pathogenic/Likely pathogenic rs1057519942 3:178921548-178921548 3:179203760-179203760
16 NRAS NM_002524.5(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 1:115258744-115258744 1:114716123-114716123
17 MAP2K1 NM_002755.3(MAP2K1): c.171G> C (p.Lys57Asn) single nucleotide variant Likely pathogenic rs869025608 15:66727455-66727455 15:66435117-66435117
18 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 7:148508728-148508728 7:148811636-148811636
19 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 7:148508727-148508727 7:148811635-148811635
20 MYC NM_002467.6(MYC): c.218C> T (p.Thr73Ile) single nucleotide variant Likely pathogenic rs756091827 8:128750681-128750681 8:127738435-127738435
21 B2M NM_004048.3(B2M): c.3G> A (p.Met1Ile) single nucleotide variant Likely pathogenic rs1057519877 15:45003747-45003747 15:44711549-44711549
22 B2M NM_004048.3(B2M): c.1A> G (p.Met1Val) single nucleotide variant Likely pathogenic rs1023835002 15:45003745-45003745 15:44711547-44711547
23 B2M NM_004048.3(B2M): c.1A> T (p.Met1Leu) single nucleotide variant Likely pathogenic rs1023835002 15:45003745-45003745 15:44711547-44711547
24 B2M NM_004048.3(B2M): c.2T> C (p.Met1Thr) single nucleotide variant Likely pathogenic rs1057519879 15:45003746-45003746 15:44711548-44711548
25 B2M NM_004048.3(B2M): c.2T> G (p.Met1Arg) single nucleotide variant Likely pathogenic rs1057519879 15:45003746-45003746 15:44711548-44711548
26 EZH2 NM_004456.4(EZH2): c.1922A> T (p.Glu641Val) single nucleotide variant Likely pathogenic rs1057519894 7:148508742-148508742 7:148811650-148811650
27 EZH2 NM_004456.4(EZH2): c.1922A> C (p.Glu641Ala) single nucleotide variant Likely pathogenic rs1057519894 7:148508742-148508742 7:148811650-148811650
28 MAP2K1 NM_002755.3(MAP2K1): c.170A> C (p.Lys57Thr) single nucleotide variant Likely pathogenic rs1057519909 15:66727454-66727454 15:66435116-66435116
29 MYC NM_002467.6(MYC): c.217A> C (p.Thr73Pro) single nucleotide variant Likely pathogenic rs750664148 8:128750680-128750680 8:127738434-127738434
30 MYC NM_002467.6(MYC): c.173C> T (p.Pro58Leu) single nucleotide variant Likely pathogenic rs1057519918 8:128750636-128750636 8:127738390-127738390
31 PIK3CA NM_006218.4(PIK3CA): c.1031T> G (p.Val344Gly) single nucleotide variant Likely pathogenic rs1057519941 3:178921549-178921549 3:179203761-179203761
32 PIK3CA NM_006218.4(PIK3CA): c.1031T> C (p.Val344Ala) single nucleotide variant Likely pathogenic rs1057519941 3:178921549-178921549 3:179203761-179203761
33 RHOA NM_001664.4(RHOA): c.13C> T (p.Arg5Trp) single nucleotide variant Likely pathogenic rs1057519952 3:49413010-49413010 3:49375577-49375577
34 RHOA NM_001664.4(RHOA): c.14G> A (p.Arg5Gln) single nucleotide variant Likely pathogenic rs1057519953 3:49413009-49413009 3:49375576-49375576
35 RHOA NM_001664.4(RHOA): c.14G> T (p.Arg5Leu) single nucleotide variant Likely pathogenic rs1057519953 3:49413009-49413009 3:49375576-49375576
36 RHOA NM_001664.4(RHOA): c.125A> G (p.Tyr42Cys) single nucleotide variant Likely pathogenic rs1057519954 3:49412898-49412898 3:49375465-49375465
37 RHOA NM_001664.4(RHOA): c.125A> C (p.Tyr42Ser) single nucleotide variant Likely pathogenic rs1057519954 3:49412898-49412898 3:49375465-49375465
38 RHOA NM_001664.4(RHOA): c.125A> T (p.Tyr42Phe) single nucleotide variant Likely pathogenic rs1057519954 3:49412898-49412898 3:49375465-49375465
39 TP53 NM_000546.5(TP53): c.722C> A (p.Ser241Tyr) single nucleotide variant Likely pathogenic rs28934573 17:7577559-7577559 17:7674241-7674241
40 TP53 NM_000546.5(TP53): c.721T> C (p.Ser241Pro) single nucleotide variant Likely pathogenic rs1057520002 17:7577560-7577560 17:7674242-7674242
41 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 17:7577559-7577559 17:7674241-7674241
42 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 7:148508727-148508727 7:148811635-148811635
43 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 7:148508728-148508728 7:148811636-148811636
44 TP53 NM_000546.5(TP53): c.614A> C (p.Tyr205Ser) single nucleotide variant Likely pathogenic rs1057520007 17:7578235-7578235 17:7674917-7674917
45 TP53 NM_000546.5(TP53): c.614A> T (p.Tyr205Phe) single nucleotide variant Likely pathogenic rs1057520007 17:7578235-7578235 17:7674917-7674917
46 TP53 NM_000546.5(TP53): c.614A> G (p.Tyr205Cys) single nucleotide variant Likely pathogenic rs1057520007 17:7578235-7578235 17:7674917-7674917
47 TP53 NM_000546.5(TP53): c.721T> G (p.Ser241Ala) single nucleotide variant Likely pathogenic rs1057520002 17:7577560-7577560 17:7674242-7674242
48 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 17:7577559-7577559 17:7674241-7674241
49 TP53 NM_000546.5(TP53): c.845G> A (p.Arg282Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs730882008 17:7577093-7577093 17:7673775-7673775
50 TP53 NM_000546.5(TP53): c.613T> C (p.Tyr205His) single nucleotide variant Uncertain significance rs1057520008 17:7578236-7578236 17:7674918-7674918

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

74
# Symbol AA change Variation ID SNP ID
1 BRAF p.Gly469Ala VAR_018620 rs121913355
2 BRAF p.Gly469Arg VAR_018622 rs121913357
3 BRAF p.Asp594Gly VAR_018624 rs121913338
4 CASP10 p.Ala414Val VAR_037430 rs28936699

Copy number variations for Lymphoma, Non-Hodgkin, Familial from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 164351 22 36286416 36295356 Translate CEP1 Non-Hodgkin''s lymphomas

Expression for Lymphoma, Non-Hodgkin, Familial

Search GEO for disease gene expression data for Lymphoma, Non-Hodgkin, Familial.

Pathways for Lymphoma, Non-Hodgkin, Familial

Pathways related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 TP53 PTPRC PIK3CA NRAS MYC IRF4
2
Show member pathways
13.34 TP53 PIK3CA NRAS MYC IRF4 CCND1
3
Show member pathways
13.21 TP53 PTPRC NRAS MYC CCND1 BRAF
4
Show member pathways
12.97 TP53 PIK3CA NRAS MYC CCND1 CASP10
5
Show member pathways
12.86 TP53 PIK3CA NRAS MYC CCND1 BRAF
6 12.79 TP53 PIK3CA NRAS MYC CCND1 BRAF
7
Show member pathways
12.74 TP53 PIK3CA NRAS MYC CCND1 BRAF
8
Show member pathways
12.74 TP53 PRF1 PIK3CA NRAS MYC IRF4
9
Show member pathways
12.72 TP53 PIK3CA NRAS NPM1 BRAF
10
Show member pathways
12.68 TP53 PIK3CA NRAS CCND1 BRAF ALK
11
Show member pathways
12.56 PTPRC PIK3CA NRAS IRF4 BCL10
12 12.55 PTPRC PAX5 IRF4 BCL6 BCL10
13 12.52 TP53 PIK3CA NRAS MYC CCND1
14
Show member pathways
12.51 TP53 PIK3CA NRAS MYC CCND1 BRAF
15
Show member pathways
12.47 PIK3CA NRAS MYC CCND1
16
Show member pathways
12.44 TP53 PIK3CA NRAS CASP10
17
Show member pathways
12.39 TP53 PIK3CA MYC CCND1
18
Show member pathways
12.39 PTPRC PIK3CA NRAS MYC CCND1
19 12.35 TP53 PIK3CA NRAS MYC CCND1
20
Show member pathways
12.33 PTPRC PIK3CA NRAS BCL6
21 12.3 TP53 PIK3CA NRAS CCND1
22 12.26 TP53 PAX5 MYC BCL6
23 12.18 TP53 MYC CCND1 BRAF
24
Show member pathways
12.17 TP53 PIK3CA NRAS BRAF
25 12.15 TP53 PIK3CA NRAS MYC CCND1
26
Show member pathways
12.13 TP53 NRAS MYC BRAF
27 12.12 TP53 PIK3CA NRAS MYC CCND1
28 12.12 TP53 RAD54L MYC CCND1 BRAF
29
Show member pathways
12.12 TP53 PIK3CA NRAS MYC CCND1 BRAF
30 12.11 TP53 PIK3CA NRAS MYC CCND1 BRAF
31
Show member pathways
12.04 PIK3CA NRAS CCND1 BRAF BCL6
32 11.91 TP53 PIK3CA NRAS MYC CCND1
33 11.9 PIK3CA NRAS CCND1
34 11.86 TP53 PIK3CA MYC CCND1
35 11.86 TP53 MYC IRF4 CCND1 BCL6
36 11.84 TP53 MYC CCND1
37 11.81 TP53 NRAS MYC CCND1 BRAF
38 11.8 TP53 NPM1 MYC
39
Show member pathways
11.8 PIK3CA NRAS CASP10 BRAF
40 11.77 PAX5 NRAS MYC CCND1
41 11.75 PTPRC MS4A1 IRF4
42 11.71 PIK3CA MYC BRAF
43
Show member pathways
11.7 PRF1 PIK3CA MYC
44 11.7 TP53 PIK3CA NRAS MYC
45 11.69 TP53 PIK3CA MYC
46 11.67 PIK3CA IRF4 BCL6
47
Show member pathways
11.62 PTPRC PIK3CA NRAS MYC IRF4 BRAF
48 11.58 TP53 PTPRC NRAS BCL10
49 11.58 PIK3CA CCND1 BRAF
50 11.58 TP53 PIK3CA CCND1

GO Terms for Lymphoma, Non-Hodgkin, Familial

Cellular components related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.1 TP53 RAD54L NPM1 MYC BCL10 ALK

Biological processes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 regulation of gene expression GO:0010468 9.81 PTPRC PIK3CA MYC FAS-AS1
2 negative regulation of apoptotic process GO:0043066 9.77 TP53 NPM1 MYC BRAF BCL6
3 protein localization GO:0008104 9.7 TP53 NPM1 BCL6
4 cellular response to drug GO:0035690 9.65 TP53 MYC BRAF
5 T cell receptor signaling pathway GO:0050852 9.62 PTPRC PIK3CA BRAF BCL10
6 cellular response to UV GO:0034644 9.58 TP53 NPM1 MYC
7 determination of adult lifespan GO:0008340 9.56 TP53 RAD54L
8 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.55 PTPRC IRF4
9 regulation of apoptotic process GO:0042981 9.55 TP53 CASP10 BCL6 BCL10 ALK
10 DNA strand renaturation GO:0000733 9.49 TP53 RAD54L
11 mitotic G1 DNA damage checkpoint GO:0031571 9.46 TP53 CCND1
12 re-entry into mitotic cell cycle GO:0000320 9.43 MYC CCND1
13 response to gamma radiation GO:0010332 9.43 TP53 PTPRC MYC
14 cellular response to DNA damage stimulus GO:0006974 9.43 TP53 RAD54L RAD54B MYC CCND1 BCL6
15 regulation of B cell receptor signaling pathway GO:0050855 9.24 PAX5
16 cytokine-mediated signaling pathway GO:0019221 9.1 TP53 PIK3CA MYC IRF4 CCND1 BCL6

Molecular functions related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 TP53 RAD54L RAD54B PTPRC PRF1 PIK3CA
2 protein kinase binding GO:0019901 9.55 TP53 PTPRC NPM1 CCND1